← Back to headlines
BridgeBio Administers First Dose in Acoramidis Heart Study
BridgeBio Therapeutics has dosed the first patient in a clinical trial evaluating acoramidis for heart disease, marking a key milestone in the drug's development pipeline.
26 Aug, 11:36 — 26 Aug, 11:36
Sources
Showing 1 of 1 sources
Related Stories
TWG Global Denies Fraud Allegations Amid Ongoing Federal Investigation
17m ago
Bill Gates Warns of Unprepared World as He Proposes New AI Safeguards
21m ago
U.S. inflation rises again and stays well above Fed’s target. Rate hike might be in play.
23m ago
US Core Inflation Holds at 3.3% in July Amid Persistent Energy Costs
26m ago